LGVN Stock Price, Longeveron Inc. Quote, Chart

Market Summary

USD1.28-0.01

Market Closed

-0.78%

LGVN Alerts

3 major insider buys recently.

LGVN Stock Price

View Fullscreen

LGVN RSI Chart

LGVN Valuation

Market Cap

3.2M

Price/Earnings (Trailing)

-0.15

Price/Sales (Trailing)

4.54

Price/Free Cashflow

-0.19

LGVN Price/Sales (Trailing)

LGVN Profitability

Operating Margin

28.91%

Return on Equity

-686.16%

Return on Assets

-215.18%

Free Cashflow Yield

-513.3%

LGVN Fundamentals

LGVN Revenue

Revenue (TTM)

709.0K

Rev. Growth (Yr)

96.42%

Rev. Growth (Qtr)

769.84%

LGVN Earnings

Earnings (TTM)

-20.9M

Earnings Growth (Yr)

11.77%

Earnings Growth (Qtr)

31.98%

Breaking Down LGVN Revenue

Last 7 days

-12.3%

Last 30 days

-38.8%

Last 90 days

-75.8%

Trailing 12 Months

-96.0%

How does LGVN drawdown profile look like?

LGVN Financial Health

Current Ratio

0.71

Debt/Equity

0.62

Debt/Cashflow

-8.57

LGVN Investor Care

Shares Dilution (1Y)

3.65%

Diluted EPS (TTM)

-9.61

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	961.0K	877.0K	793.0K	709.0K
2022	1.3M	937.0K	970.0K	1.1M
2021	0	0	0	1.3M
2020	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Longeveron Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 02, 2024	locklear lisa	sold (taxes)	-1,160	2.83	-410	chief financial officer
May 02, 2024	agafonova nataliya	sold (taxes)	-871	2.83	-308	chief medical officer
Apr 11, 2024	soffer rock	bought	75,000	2.35	31,915	-
Apr 11, 2024	hashad mohamed wa'el ahmed	bought	24,999	2.35	10,638	chief executive officer
Apr 11, 2024	hare joshua	bought	99,999	2.35	42,553	chief scientific officer
Apr 10, 2024	hare joshua	bought	250,000	2.35	106,383	chief scientific officer
Apr 10, 2024	soffer rock	bought	250,000	2.35	106,383	-
Mar 12, 2024	hashad mohamed wa'el ahmed	acquired	-	-	80,200	chief executive officer
Mar 12, 2024	hashad mohamed wa'el ahmed	sold (taxes)	-17,747	0.54	-32,866	chief executive officer
Jan 10, 2024	ross cathy	bought	6,544	1.3089	5,000	-

Which funds bought or sold LGVN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	STATE STREET CORP	sold off	-100	-20,128	-	-%
May 15, 2024	CITADEL ADVISORS LLC	sold off	-100	-43,864	-	-%
May 15, 2024	Royal Bank of Canada	new	-	-	-	-%
May 15, 2024	Royal Bank of Canada	sold off	-100	-	-	-%
May 15, 2024	Tower Research Capital LLC (TRC)	new	-	8,434	8,434	-%
May 15, 2024	Tower Research Capital LLC (TRC)	sold off	-100	-9,264	-	-%
May 15, 2024	ARMISTICE CAPITAL, LLC	sold off	-100	-2,496,960	-	-%
May 15, 2024	Schonfeld Strategic Advisors LLC	sold off	-100	-17,000	-	-%
May 15, 2024	TOWNSQUARE CAPITAL LLC	sold off	-100	-19,652	-	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-5,311	-	-%

Are Funds Buying or Selling LGVN?

Are funds buying LGVN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own LGVN

No. of Funds

LGVN Alerts

3 major insider buys recently.

Unveiling Longeveron Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 17, 2024	intracoastal capital, llc	4.99%	174,054	SC 13G
Apr 15, 2024	hare joshua	25.7%	1,084,888	SC 13D/A
Feb 14, 2024	armistice capital, llc	7.31%	1,836,000	SC 13G
Dec 18, 2023	hare joshua	48.3%	7,988,167	SC 13D/A
May 25, 2022	soffer donald m	0%	0	SC 13D/A

Recent SEC filings of Longeveron Inc.

View All Filings

Date Filed	Form Type	Document
May 14, 2024	10-Q	Quarterly Report
May 14, 2024	3	Insider Trading
May 14, 2024	4	Insider Trading
May 10, 2024	8-K	Current Report
May 06, 2024	4	Insider Trading
May 06, 2024	4	Insider Trading
Apr 30, 2024	S-1	Initial Public Offering
Apr 25, 2024	D	D
Apr 18, 2024	8-K	Current Report
Apr 17, 2024	EFFECT	EFFECT

Peers (Alternatives to Longeveron Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Longeveron Inc. News

Latest updates

Longeveron Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Revenue	769.8%	548	63.00	150	215	279	291	265	126	370	209	232	489	376	1,121	1,865	876	1,708
Cost Of Revenue	236.9%	219	65.00	96.00	124	203	109	173	306	205	140	68.00	281	227	651	1,492	764	896
Gross Profit	16550.0%	329	-2.00	54.00	93.00	76.00	13.00	92.00	160	165	69.00	164	208	149	529	373	112	812
Operating Expenses	-18.7%	4,419	5,438	5,215	5,805	4,792	5,254	5,279	4,381	3,559	4,101	5,069	5,270	3,607	1,911	1,331	1,338	1,025
S&GA Expenses	-100.0%	-	203	280	143	157	285	245	234	287	834	25.00	53.00	550	59.00	44.00	47.00	50.00
R&D Expenses	2.9%	2,219	2,156	1,843	2,287	2,780	3,331	2,960	1,720	1,292	1,734	2,048	1,960	1,350	1,155	585	642	289
Interest Expenses	-	-	-	-	-	-	1,397	-	-	-	1.00	1.00	2.00	-	-	4.00	-	-
Net Income	32.0%	-4,100	-6,028	-5,106	-5,632	-4,647	-4,457	-5,244	-5,624	-3,510	-4,069	-4,855	-5,010	-3,111	-1,355	-938	-1,216	-213
Net Income Margin	2.6%	-29.43*	-30.20*	-25.02*	-22.78*	-20.78*	-17.90*	-19.02*	-19.27*	-13.42*	-13.05*	-	-	-	-	-	-	-
Free Cashflow	25.5%	-3,102	-4,161	-4,559	-4,693	-5,890	-2,374	-4,612	-3,353	-4,199	-1,593	-2,358	-2,939	-3,019	-492	-246	-1,229	-528

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet														(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	-19.7%	9,697	12,078	11,625	17,093	21,808	27,413	30,515	35,325	39,173	42,766	27,150	29,857	32,432	9,240
Current Assets	-35.8%	3,757	5,848	5,044	10,292	14,870	20,280	23,237	28,238	31,867	35,380	19,665	22,111	25,297	1,849
Cash Equivalents	-60.8%	1,940	4,949	1,967	2,747	4,984	10,503	13,574	20,224	22,132	25,658	9,738	16,833	24,461	816
Net PPE	-7.2%	2,348	2,529	2,544	2,717	2,810	2,949	3,064	2,835	2,966	3,062	3,070	3,234	3,417	3,597
Liabilities	24.7%	6,656	5,337	4,993	5,830	5,490	6,910	5,900	5,944	4,867	5,313	4,817	5,207	5,937	7,283
Current Liabilities	36.2%	5,295	3,889	3,394	4,082	3,595	4,869	3,715	3,618	2,400	2,708	1,932	2,185	2,781	3,830
Long Term Debt	-	-	-	-	-	1,895	2,041	2,185	2,326	-	2,605	143	145	146	311
Shareholder's Equity	-54.9%	3,041	6,741	6,632	11,263	16,318	20,503	24,615	29,381	34,306	37,453	22,333	24,650	26,495	1,957
Retained Earnings	-4.8%	-89,042	-84,984	-78,956	-73,052	-67,420	-62,773	-58,316	-53,072	-47,448	-43,938	-39,869	-35,014	-30,004	-
Additional Paid-In Capital	0.3%	92,080	91,800	85,976	84,729	84,116	83,712	83,010	82,532	81,833	81,470	62,283	59,745	56,580	-
Shares Outstanding	15.6%	2,514	2,173	2,118	2,107	2,103	2,097	2,095	2,093	2,091	1,892	1,854	1,825	-	1,602
Float	-	-	-	-	19,016	-	-	-	18,000	-	-	-	26,000	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Cashflow From Operations	22.8%	-3,086	-3,997	-4,556	-4,601	-5,848	-2,308	-4,234	-3,275	-4,152	-1,281	-2,371	-2,952	-3,032	-505	-233	-1,228	-398
Share Based Compensation	-	295	-	-	-	421	476	293	-	-	-4,681	5,714	-1,001	1,265	-	-	31.00	13.00
Cashflow From Investing	-99.1%	14.00	1,564	3,826	2,450	346	-570	-2,389	1,515	767	-1,315	-4,724	-	-	-40.00	-40.00	-41.00	-140
Cashflow From Financing	-98.8%	63.00	5,415	-50.00	-86.00	-17.00	-193	-27.00	-148	-141	18,516	-	-19.00	26,677	-33.00	8.00	450	1,150

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

LGVN Income Statement

2024-03-31

Condensed Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues
Total revenues	$ 548	$ 279
Cost of revenues	219	203
Gross profit	329	76
Operating expenses
General and administrative	2,200	2,012
Research and development	2,219	2,780
Total operating expenses	4,419	4,792
Loss from operations	(4,090)	(4,716)
Other income and (expenses)
Other income, net	32	69
Total other income, net	32	69
Net loss	$ (4,058)	$ (4,647)
Basic and diluted net loss per share (in Dollars per share)	$ (1.61)	$ (2.21)
Basic and diluted weighted average common shares outstanding (in Shares)	2,513,587	2,103,362
Clinical trial revenue
Revenues
Total revenues	$ 515	$ 238
Contract manufacturing revenue
Revenues
Total revenues	33
Grant revenue
Revenues
Total revenues		$ 41

LGVN Balance Sheet

2024-03-31

Condensed Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Assets
Cash and cash equivalents	$ 1,940	$ 4,949
Marketable securities	351	412
Prepaid expenses and other current assets	1,288	376
Accounts and grants receivable	178	111
Total current assets	3,757	5,848
Property and equipment, net	2,348	2,529
Intangible assets, net	2,263	2,287
Operating lease asset	1,139	1,221
Other assets	190	193
Total assets	9,697	12,078
Current liabilities:
Accounts payable	1,467	638
Accrued expenses	2,401	2,152
Current portion of lease liability	601	593
Deferred revenue	826	506
Total current liabilities	5,295	3,889
Long-term liabilities:
Lease liability	1,295	1,448
Other liabilities	66
Total long-term liabilities	1,361	1,448
Total liabilities	6,656	5,337
Commitments and contingencies (Note 9)
Stockholders’ equity:
Preferred stock, $0.001 par value per share, 5,000,000 shares authorized, no shares issued and outstanding at March 31, 2024, and December 31, 2023.
Additional paid-in capital	92,080	91,823
Stock subscription receivable		(100)
Accumulated deficit	(89,042)	(84,984)
Accumulated other comprehensive gain	1
Total stockholders’ equity	3,041	6,741
Total liabilities and stockholders’ equity	9,697	12,078
Class A common stock
Stockholders’ equity:
Common stock value	1	1
Class B common stock
Stockholders’ equity:
Common stock value	$ 1	$ 1

About Longeveron Inc.

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, an allogeneic medicinal signaling cell therapy product isolated from the bone marrow of young, healthy adult donors. It is conducting Phase 1, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami, Florida.

CEO	Mr. Mohamed Wa'el Ahmed Hashad
WEBSITE	https://longeveron.com
INDUSTRY	Biotechnology
EMPLOYEES	19

Longeveron Inc. Frequently Asked Questions

What is the ticker symbol for Longeveron Inc.? What does LGVN stand for in stocks?

LGVN is the stock ticker symbol of Longeveron Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Longeveron Inc. (LGVN)?

As of Fri May 17 2024, market cap of Longeveron Inc. is 3.22 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LGVN stock?

You can check LGVN's fair value in chart for subscribers.

What is the fair value of LGVN stock?

You can check LGVN's fair value in chart for subscribers. The fair value of Longeveron Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Longeveron Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LGVN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Longeveron Inc. a good stock to buy?

The fair value guage provides a quick view whether LGVN is over valued or under valued. Whether Longeveron Inc. is cheap or expensive depends on the assumptions which impact Longeveron Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LGVN.

What is Longeveron Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, LGVN's PE ratio (Price to Earnings) is -0.15 and Price to Sales (PS) ratio is 4.54. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LGVN PE ratio will change depending on the future growth rate expectations of investors.